Stay updated with breaking news from Recursion Pharmaceuticals Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) CEO Christopher Gibson sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $8.42, for a total transaction of $421,000.00. Following the completion of the sale, the chief executive officer now owns […]
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) CEO Christopher Gibson sold 50,000 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $8.42, for a total value of $421,000.00. Following the completion of the transaction, the chief executive officer now directly owns 758,738 […]
Lingotto Investment Management LLP lifted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 141.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,875,077 shares of the company’s stock after buying an additional 1,100,000 shares during the period. Recursion […]
Recursion Pharmaceuticals is an NVIDIA Corp (NASDAQ:NVDA) partner that will use the semiconductor giant's chips and technology for drug discovery.
The AI-led stock rally that rewarded mega-cap technology stocks has finally started to trickle down to other industry players that were seemingly not related to the AI and tech industry.